Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

Avet‐Loiseau, Hervé; Leleu, Xavier; Roussel, Murielle; Moreau, Philippe; Guérin‐Charbonnel, Catherine; Caillot, Denis; Marit, Gérald; Benboubker, Lotfi; Voillat, Laurent; Mathiot, Claire; Kolb, Brigitte; Macro, Margaret; Campion, L.; Wetterwald, Marc; Stoppa, Anne‐Marie; Hulin, Cyrille; Façon, Thierry; Attal, Michel; Minvielle, Stéphane; Harousseau, Jean‐Luc

doi:10.1200/jco.2010.28.3945

Public

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

Published in Journal of Clinical Oncology • Jul 20, 2010

Authors:

Hervé Avet‐Loiseau

Xavier Leleu

Murielle Roussel

Abstract

PURPOSE: Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic p...

Subject

Bortezomib

Medicine

Dexamethasone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!